Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patientsFederica Varsaldi, Grazia Lombardi, Marja‐Liisa Dahl et al.|European Journal of Clinical Pharmacology|2006Cited by 96
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?Laura Magliulo, Maria Gabriella Scordo, Marja‐Liisa Dahl et al.|European Journal of Clinical Pharmacology|2010Cited by 45
Impact of CYP2D6 polymorphism on plasma levels of donepezil: clinical relevance in patients with Alzheimer’s diseaseM.G. Scordo, Giuseppe Lombardi, M-L. Dahl et al.|Unknown|2004Cited by 0
Association between apolipoprotein E polymorphism and Alzheimer disease in Novara, ItalyFederica Varsaldi, Giuseppe Lombardi, Gianluca Miglio et al.|Unknown|2005Cited by 0